SEC Tracker
Get the app
Person · CIK 1518611

William John Sibold

President and CEO at Madrigal Pharmaceuticals

Earlier: Avanir Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$18.9M
Noticed on Form 144$14M
Bought on Form 4$0
Companies2

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Madrigal Pharmaceuticals MDGLCommon StockDirectly197,746Sep 11, 2026 · Filing · EDGAR
Avanir PharmaceuticalsCommon StockDirectly20,000May 3, 2011 · Filing · EDGAR

Sold and noticed by quarter

William John Sibold: dollars sold on Form 4 and noticed on Form 144 per quarter, Q3 2024 to Q4 2026$7.6M$0Q3 2024: $1.6M noticed on Form 144Q3 2024: $1.6M sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $539K noticed on Form 144Q1 2025: $531K sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $6.3M noticed on Form 144Q3 2025: $6.3M sold on Form 4Q4 2025: $1.4M noticed on Form 144Q4 2025: $1.4M sold on Form 4Q1 2026: $1.5M noticed on Form 144Q1 2026: $1.5M sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $2.8M noticed on Form 144Q3 2026: $7.6M sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q3 2024Q1 2025Q3 2025Q1 2026Q3 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q3 2026$7.6M$2.8M
Q1 2026$1.5M$1.5M
Q4 2025$1.4M$1.4M
Q3 2025$6.3M$6.3M
Q1 2025$531K$539K
Q3 2024$1.6M$1.6M

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · 10b5-1 plan adopted Jun 5, 2026 · 1 notice
Sep 11, 20265,221 · ~$2.8MSep 11, 2026Sold as noticed Sold 5,180 in 11 sales, Sep 9 to Sep 11 · $2.8M Form 4Filing · EDGAR
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 6 notices
Mar 6, 20261,663 · ~$731KMar 6, 2026Sold as noticed Sold 1,663 at $431.94 on Mar 6 · $718K Form 4Filing · EDGAR
Jan 26, 20261,577 · ~$758KJan 26, 2026Sold as noticed Sold 1,577 at $492.42 on Jan 26 · $777K Form 4Filing · EDGAR
Dec 4, 20252,400 · ~$1.4MDec 4, 2025Sold as noticed Sold 2,400 at $575.34 on Dec 4 · $1.4M Form 4Filing · EDGAR
Sep 9, 20257,279 · ~$3.3MSep 9, 2025Sold as noticed Sold 7,279 at $445.63 on Sep 9 · $3.2M Form 4Filing · EDGAR
Jan 24, 20251,584 · ~$539KJan 24, 2025Sold as noticed Sold 1,584 at $335.24 on Jan 24 · $531K Form 4Filing · EDGAR
Sep 10, 20246,363 · ~$1.6MSep 9, 2024Sold as noticed Sold 6,363 at $243.83 on Sep 9 · $1.6M Form 4Filing · EDGAR
Madrigal Pharmaceuticals MDGL · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 15, 2024 · 1 notice
Aug 21, 20257,616 · ~$3MAug 21, 2025Sold as noticed Sold 7,616 in 2 sales, Aug 21 to Aug 21 · $3M Form 4Filing · EDGAR
Sales without a matching Form 144 · 23 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 120 at $546.38 on Sep 11, 2026 · $66K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 761 at $544.83 on Sep 11, 2026 · $415K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 1,539 at $544.02 on Sep 11, 2026 · $837K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 1,202 at $542.60 on Sep 11, 2026 · $652K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 368 at $541.64 on Sep 11, 2026 · $199K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 687 at $540.59 on Sep 11, 2026 · $371K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 160 at $537.62 on Sep 11, 2026 · $86K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 218 at $535.94 on Sep 11, 2026 · $117K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 106 at $534.06 on Sep 11, 2026 · $57K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 160 at $542.55 on Sep 9, 2026 · $87K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 362 at $541.65 on Sep 9, 2026 · $196K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 505 at $540.19 on Sep 9, 2026 · $273K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 215 at $539.03 on Sep 9, 2026 · $116K (10b5-1 plan)Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 280 at $555.05 on Jul 20, 2026 · $155KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 1 at $550.72 on Jul 20, 2026 · $551Filing · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 153 at $550.01 on Jul 20, 2026 · $84KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 47 at $548.87 on Jul 20, 2026 · $26KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 680 at $547.70 on Jul 20, 2026 · $372KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 269 at $547.08 on Jul 20, 2026 · $147KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 275 at $545.71 on Jul 20, 2026 · $150KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 545 at $544.71 on Jul 20, 2026 · $297KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 110 at $543.79 on Jul 20, 2026 · $60KFiling · EDGAR
———Sold without notice Madrigal Pharmaceuticals (MDGL): Sold 140 at $542.75 on Jul 20, 2026 · $76KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Madrigal Pharmaceuticals MDGL President and CEO · filings 2023 to 2026 · sold $18.9M · $14M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Sep 11, 2026Sale under a 10b5-1 plan−60$533.09$32K202,907 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−106$534.06$57K202,801 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−218$535.94$117K202,583 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−160$537.62$86K202,423 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−687$540.59$371K201,736 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−368$541.64$199K201,368 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−1,202$542.60$652K200,166 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−1,539$544.02$837K198,627 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−761$544.83$415K197,866 directFiling · EDGAR
Sep 11, 2026Sale under a 10b5-1 plan−120$546.38$66K197,746 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−131$527.88$69K209,198 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−347$529.27$184K208,851 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−522$530.23$277K208,329 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−368$531.99$196K207,961 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−512$533.09$273K207,449 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−396$534.20$212K207,053 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−644$535.27$345K206,409 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−1,040$536.11$558K205,369 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−640$537.17$344K204,729 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−520$538.30$280K204,209 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−215$539.03$116K203,994 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−505$540.19$273K203,489 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−362$541.65$196K203,127 directFiling · EDGAR
Sep 9, 2026Sale under a 10b5-1 plan−160$542.55$87K202,967 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−140$542.75$76K211,689 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−110$543.79$60K211,579 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−545$544.71$297K211,034 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−275$545.71$150K210,759 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−269$547.08$147K210,490 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−680$547.70$372K209,810 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−47$548.87$26K209,763 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−153$550.01$84K209,610 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−1$550.72$551209,609 directFiling · EDGAR
Jul 20, 2026Open-market or private sale−280$555.05$155K209,329 directFiling · EDGAR
Jul 17, 2026Option or RSU exercised or converted+50,000211,829 directFiling · EDGAR
Jul 17, 2026Option or RSU exercised or converted
Performance Restricted Stock Units
−50,0000 directFiling · EDGAR
Mar 6, 2026Open-market or private sale−1,663$431.94$718K161,829 directFiling · EDGAR
Mar 4, 2026Grant or award from the company+14,995163,492 directFiling · EDGAR
Mar 4, 2026Grant or award from the company
Stock Option (Right to Buy)
+18,74318,743 directFiling · EDGAR
Jan 26, 2026Open-market or private sale−1,577$492.42$777K148,497 directFiling · EDGAR
Dec 4, 2025Open-market or private sale−2,400$575.34$1.4M150,074 directFiling · EDGAR
Dec 3, 2025Option or RSU exercised or converted+50,000152,474 directFiling · EDGAR
Dec 3, 2025Option or RSU exercised or converted
Performance Restricted Stock Units
−50,0000 directFiling · EDGAR
Sep 9, 2025Open-market or private sale−7,279$445.63$3.2M102,474 directFiling · EDGAR
Aug 21, 2025Sale under a 10b5-1 plan−6,485$400.03$2.6M110,884 directFiling · EDGAR
Aug 21, 2025Sale under a 10b5-1 plan−1,131$401.00$454K109,753 directFiling · EDGAR
Mar 5, 2025Grant or award from the company+13,066117,369 directFiling · EDGAR
Mar 5, 2025Grant or award from the company
Stock Option (Right to Buy)
+22,00922,009 directFiling · EDGAR
Feb 27, 2025Option or RSU exercised or converted+50,000104,303 directFiling · EDGAR
Feb 27, 2025Option or RSU exercised or converted
Performance Restricted Stock Units
−50,0000 directFiling · EDGAR
Jan 24, 2025Open-market or private sale−1,584$335.24$531K54,303 directFiling · EDGAR
Sep 9, 2024Open-market or private sale−6,363$243.83$1.6M55,887 directFiling · EDGAR
Jan 23, 2024Grant or award from the company+12,25062,250 directFiling · EDGAR
Jan 23, 2024Grant or award from the company
Stock Option (Right to Buy)
+18,45918,459 directFiling · EDGAR
Jan 23, 2024Grant or award from the company
Market Stock Unit
+12,25012,250 directFiling · EDGAR
Sep 11, 2023Grant or award from the company+50,00050,000 directFiling · EDGAR
Sep 11, 2023Grant or award from the company
Performance Restricted Stock Units
+50,00050,000 directFiling · EDGAR

Avanir Pharmaceuticals Other · filings 2011 to 2011

DateTransactionSharesPriceValueHeld afterSource
May 3, 2011Grant or award from the company+20,00020,000 directFiling · EDGAR
May 3, 2011Grant or award from the company
Stock Option
+250,000250,000 directFiling · EDGAR
All 26 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Sep 11, 2026Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 11, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 9, 2026Form 144
Could not read
EDGAR
Jul 20, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jul 20, 2026Form 144
Could not read
EDGAR
Mar 6, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Mar 6, 2026Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 26, 2026Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 26, 2026Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Dec 4, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Dec 4, 2025Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 9, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 9, 2025Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 21, 2025Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Aug 21, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Mar 7, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Feb 28, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 27, 2025Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 24, 2025Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 11, 2024Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 10, 2024Form 144Madrigal Pharmaceuticals MDGLFiling · EDGAR
Jan 25, 2024Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 13, 2023Form 4Madrigal Pharmaceuticals MDGLFiling · EDGAR
Sep 13, 2023Form 3Madrigal Pharmaceuticals MDGLFiling · EDGAR
May 5, 2011Form 4Avanir PharmaceuticalsFiling · EDGAR
Apr 21, 2011Form 3Avanir PharmaceuticalsFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.